Entecavir monotherapy versus de novo combination of lamivudine and adefovir for the treatment of naive HBeAg-positive chronic hepatitis B patients with High HBV viral load (the Climber study).
Latest Information Update: 24 Apr 2016
Price :
$35 *
At a glance
- Drugs Adefovir dipivoxil (Primary) ; Entecavir (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms Climber
- 21 May 2012 Planned end date 31 Aug 2014 added as reported by Chinese Clinical Trial Register.
- 10 May 2012 New trial record